Unfortunately, although there is genetic data available for cSCC from melanoma patients treated with BRAFi and these have high levels of HRAS mutations22, there is no transcriptomic data available to explore whether the proportion of tumours expressing SOX2 is increased. This evidence concerns the gene SOX2 and neoplasm.